articleThe LancetFeb 13, 2026Closed access

Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study

Memorial Sloan Kettering Cancer Center · UPMC Hillman Cancer Center · +33 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

No related works found for this paper.